CN101662937B - 癌症治疗方法 - Google Patents
癌症治疗方法 Download PDFInfo
- Publication number
- CN101662937B CN101662937B CN200880012425.7A CN200880012425A CN101662937B CN 101662937 B CN101662937 B CN 101662937B CN 200880012425 A CN200880012425 A CN 200880012425A CN 101662937 B CN101662937 B CN 101662937B
- Authority
- CN
- China
- Prior art keywords
- cancer
- purposes
- leukemia
- carcinoma
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(C1CO)=C(*)C(*)=C(*)[C@@]1N=N* Chemical compound *C(C1CO)=C(*)C(*)=C(*)[C@@]1N=N* 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
细胞系 | 说明 | 化合物AIC50(ug/mL) |
CCRF-CEM | 成淋巴细胞性T细胞白血病 | 0.74 |
K562 | 慢性髓细胞性白血病 | 1.80 |
MOLT-4 | 急性成淋巴细胞性T细胞白血病 | 0.56 |
RPMI-8226 | 浆细胞瘤 | 5.90 |
SR | 免疫母细胞性大细胞白血病 | 0.77 |
细胞系 | 细胞类型 | IC50(μg/mL) | 试验形式 |
NCI-H23 | NSCLC | 13.9 | Cell Titer Glo |
HOP-92 | NSCLC | 13.5 | Cell Titer Glo |
EKVX | NSCLC | 12.7 | Cell Titer Glo |
NCI-H226 | NSCLC | 11.0 | Cell Titer Glo |
HOP-62 | NSCLC | 10.6 | Cell Titer Glo |
A549 | NSCLC | 9.10 | Cell Titer Glo |
NCI-H322M | NSCLC | 8.30 | Cell Titer Glo |
NCI-H522 | NSCLC | 5.90 | Cell Titer Glo |
NCI-H460 | NSCLC | 5.70 | Cell Titer Glo |
HepG2 | 肝细胞癌 | 5.61 | Cell Titer Glo |
Claims (40)
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89023607P | 2007-02-16 | 2007-02-16 | |
US60/890,236 | 2007-02-16 | ||
US89255207P | 2007-03-02 | 2007-03-02 | |
US60/892,552 | 2007-03-02 | ||
US90820507P | 2007-03-27 | 2007-03-27 | |
US60/908,205 | 2007-03-27 | ||
US94934707P | 2007-07-12 | 2007-07-12 | |
US60/949,347 | 2007-07-12 | ||
US95228907P | 2007-07-27 | 2007-07-27 | |
US60/952,289 | 2007-07-27 | ||
US96919207P | 2007-08-31 | 2007-08-31 | |
US60/969,192 | 2007-08-31 | ||
US97721607P | 2007-10-03 | 2007-10-03 | |
US60/977,216 | 2007-10-03 | ||
PCT/US2008/054046 WO2008101141A2 (en) | 2007-02-16 | 2008-02-15 | Cancer treatment method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101662937A CN101662937A (zh) | 2010-03-03 |
CN101662937B true CN101662937B (zh) | 2014-03-12 |
Family
ID=39690807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880012425.7A Active CN101662937B (zh) | 2007-02-16 | 2008-02-15 | 癌症治疗方法 |
Country Status (27)
Country | Link |
---|---|
US (2) | US20100075928A1 (zh) |
EP (1) | EP2124547B1 (zh) |
JP (1) | JP5511391B2 (zh) |
KR (1) | KR101447763B1 (zh) |
CN (1) | CN101662937B (zh) |
AR (1) | AR065348A1 (zh) |
AU (1) | AU2008216106B9 (zh) |
BR (1) | BRPI0807940B8 (zh) |
CA (1) | CA2678358C (zh) |
CR (1) | CR10997A (zh) |
DK (1) | DK2124547T3 (zh) |
EA (1) | EA017715B1 (zh) |
ES (1) | ES2675070T3 (zh) |
HU (1) | HUE038563T2 (zh) |
IL (2) | IL200319A (zh) |
MA (1) | MA31202B1 (zh) |
MX (1) | MX2009008822A (zh) |
NZ (1) | NZ579068A (zh) |
PE (1) | PE20081784A1 (zh) |
PL (1) | PL2124547T3 (zh) |
PT (1) | PT2124547T (zh) |
SI (1) | SI2124547T1 (zh) |
TR (1) | TR201809010T4 (zh) |
TW (1) | TW200906393A (zh) |
UY (1) | UY30915A1 (zh) |
WO (1) | WO2008101141A2 (zh) |
ZA (1) | ZA200905532B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110160130A1 (en) * | 2007-02-16 | 2011-06-30 | Connie Erickson-Miller | Cancer treatment method |
US20110129550A1 (en) * | 2007-02-16 | 2011-06-02 | Connie Erickson-Miller | Cancer treatment method |
ECSP077628A (es) | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
KR101530402B1 (ko) * | 2007-10-09 | 2015-06-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 급성 인간 골수성 백혈병 세포를 죽이는 트롬보포이에틴 수용체 효능제 (tpora) |
CA2763768A1 (en) | 2009-05-29 | 2010-12-02 | Glaxosmithkline Llc | Methods of administration of thrombopoietin agonist compounds |
JP2013538810A (ja) * | 2010-09-01 | 2013-10-17 | ノバルティス アーゲー | Hdac阻害剤と血小板減少症薬との組合せ |
WO2014150252A1 (en) | 2013-03-15 | 2014-09-25 | Ligand Pharmaceuticals Incorporated | Methods of treatment associated with the granulocyte colony-stimulating factor receptor |
AU2017261371B2 (en) * | 2016-05-06 | 2023-07-06 | Taris Biomedical Llc | Method of treating lower tract urothelial cancer |
RU2675695C1 (ru) * | 2018-03-06 | 2018-12-24 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова" Министерства здравоохранения Российской Федерации | Способ лечения рака предстательной железы высокого и очень высокого риска |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001092306A2 (en) * | 2000-05-31 | 2001-12-06 | Genzyme Corporation | Therapeutic compounds for ovarian cancer |
US20040053946A1 (en) * | 2001-01-16 | 2004-03-18 | Lackey Karen Elizabeth | Cancer treatment method |
WO2006047344A1 (en) * | 2004-10-25 | 2006-05-04 | Ligand Pharmaceuticals, Inc. | Thrombopoietin activity modulating compounds and methods |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5559235A (en) * | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
AP9300587A0 (en) * | 1992-11-12 | 1995-05-05 | Glaxo Inc | Water soluble camptothecin derivatives. |
US5681835A (en) * | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
US6316652B1 (en) * | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
AU9265698A (en) | 1997-09-02 | 1999-03-22 | Boehringer Mannheim Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia |
CN1376150A (zh) * | 1999-07-26 | 2002-10-23 | 盐野义制药株式会社 | 具有血栓形成素受体拮抗作用的药物组合物 |
ES2160560T1 (es) | 1999-11-10 | 2001-11-16 | Curacyte Ag | Colorantes o,o'-dihidroxi-azoicos como constituyentes de medicamentos para el tratamiento de trombopenias. |
PT2087907E (pt) * | 1999-11-10 | 2015-01-05 | Innatus Corp | Método e sistema para remover inibidor de citoquinas em pacientes |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
CY2010012I2 (el) | 2000-05-25 | 2020-05-29 | Novartis Ag | Μιμητικα θρομβοποιητινης |
US6887890B2 (en) * | 2000-05-30 | 2005-05-03 | Chugai Seiyaku Kabushiki Kaisha | Compounds exhibiting thrombopoietin-like activities |
CA2435143A1 (en) | 2001-01-26 | 2002-08-01 | Shionogi & Co., Ltd. | Halogen compounds having thrombopoietin receptor agonism |
EP1361220A4 (en) | 2001-01-26 | 2005-09-07 | Shionogi & Co | CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM |
JPWO2002062775A1 (ja) * | 2001-02-02 | 2004-06-10 | 山之内製薬株式会社 | 2−アシルアミノチアゾール誘導体又はその塩 |
US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
EP1435963A4 (en) * | 2001-09-24 | 2005-10-26 | Tosk Inc | CISPLATIN FORMULATIONS WITH REDUCED TOXICITY AND USE METHOD THEREFOR |
SI1466912T1 (sl) * | 2002-01-18 | 2013-08-30 | Astellas Pharma Inc. | Derivat 2-acilaminotiazola ali njegova sol |
TWI280128B (en) * | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
AU2003268687A1 (en) | 2002-09-30 | 2004-04-19 | Yamanouchi Pharmaceutical Co., Ltd. | Novel salt of 2-acylaminothiazole derivative |
EP2387998A1 (en) * | 2003-04-29 | 2011-11-23 | Glaxosmithkline LLC | Methods for treating degenerative diseases/injuries |
WO2005118551A2 (en) | 2004-05-28 | 2005-12-15 | Ligand Pharmaceuticals Inc. | Thrombopoietin activity modulating compounds and methods |
BRPI0620532A2 (pt) | 2005-11-23 | 2011-11-16 | Ligand Pharm Inc | compostos e métodos para modular a atividade de trombopoietina |
AU2007225115A1 (en) | 2006-03-15 | 2007-09-20 | Ligand Pharmaceuticals Incorporated | Synthesis of thrombopoietin activity modulating compounds |
-
2008
- 2008-02-13 UY UY30915A patent/UY30915A1/es unknown
- 2008-02-14 PE PE2008000322A patent/PE20081784A1/es not_active Application Discontinuation
- 2008-02-14 TW TW097105201A patent/TW200906393A/zh unknown
- 2008-02-14 AR ARP080100631A patent/AR065348A1/es not_active Application Discontinuation
- 2008-02-15 EA EA200970776A patent/EA017715B1/ru not_active IP Right Cessation
- 2008-02-15 US US12/527,220 patent/US20100075928A1/en not_active Abandoned
- 2008-02-15 BR BRPI0807940A patent/BRPI0807940B8/pt active IP Right Grant
- 2008-02-15 DK DK08729939.2T patent/DK2124547T3/en active
- 2008-02-15 EP EP08729939.2A patent/EP2124547B1/en active Active
- 2008-02-15 PT PT87299392T patent/PT2124547T/pt unknown
- 2008-02-15 MX MX2009008822A patent/MX2009008822A/es active IP Right Grant
- 2008-02-15 WO PCT/US2008/054046 patent/WO2008101141A2/en active Application Filing
- 2008-02-15 PL PL08729939T patent/PL2124547T3/pl unknown
- 2008-02-15 TR TR2018/09010T patent/TR201809010T4/tr unknown
- 2008-02-15 CA CA2678358A patent/CA2678358C/en active Active
- 2008-02-15 ES ES08729939.2T patent/ES2675070T3/es active Active
- 2008-02-15 SI SI200831968T patent/SI2124547T1/en unknown
- 2008-02-15 HU HUE08729939A patent/HUE038563T2/hu unknown
- 2008-02-15 CN CN200880012425.7A patent/CN101662937B/zh active Active
- 2008-02-15 JP JP2009550145A patent/JP5511391B2/ja active Active
- 2008-02-15 NZ NZ579068A patent/NZ579068A/en not_active IP Right Cessation
- 2008-02-15 AU AU2008216106A patent/AU2008216106B9/en active Active
- 2008-02-15 KR KR1020097019224A patent/KR101447763B1/ko active IP Right Grant
- 2008-07-02 US US12/166,686 patent/US20090022814A1/en not_active Abandoned
-
2009
- 2009-08-07 ZA ZA200905532A patent/ZA200905532B/xx unknown
- 2009-08-10 IL IL200319A patent/IL200319A/en active IP Right Grant
- 2009-08-26 CR CR10997A patent/CR10997A/es not_active Application Discontinuation
- 2009-08-31 MA MA32188A patent/MA31202B1/fr unknown
-
2015
- 2015-04-20 IL IL238394A patent/IL238394B/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001092306A2 (en) * | 2000-05-31 | 2001-12-06 | Genzyme Corporation | Therapeutic compounds for ovarian cancer |
US20040053946A1 (en) * | 2001-01-16 | 2004-03-18 | Lackey Karen Elizabeth | Cancer treatment method |
WO2006047344A1 (en) * | 2004-10-25 | 2006-05-04 | Ligand Pharmaceuticals, Inc. | Thrombopoietin activity modulating compounds and methods |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101662937B (zh) | 癌症治疗方法 | |
CN102405047B (zh) | 结晶型的n-{(1s)-2-氨基-1-[(3-氟苯基)甲基]乙基}-5-氯-4-(4-氯-1-甲基-1h-吡唑-5-基)-2-噻吩甲酰胺盐酸盐 | |
EP2934531A1 (en) | Combination | |
JP6355724B2 (ja) | がんを治療するためのアフレセルチブと組み合わせたエンザルタミド | |
US20190008855A1 (en) | Cancer treatment method | |
AU2014330779A1 (en) | Combination | |
US20120302579A1 (en) | Cancer treatment method | |
US20200276192A1 (en) | Cancer treatment method | |
CN104902896A (zh) | 组合 | |
US20090048318A1 (en) | Methods for treating degenerative diseases/injuries |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SMITHKLINE BEECHAM CORP. Free format text: FORMER NAME: SMITHKLINE BEECHAN CORP. |
|
CP03 | Change of name, title or address |
Address after: Delaware Patentee after: GLAXOSMITHKLINE LLC Address before: American Pennsylvania Patentee before: SMITHKLINE BEECHAM Corp. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151119 Address after: Basel, Switzerland Patentee after: NOVARTIS AG Address before: Basel, Switzerland Patentee before: NOVARTIS PHARMA AG Effective date of registration: 20151119 Address after: Basel, Switzerland Patentee after: NOVARTIS PHARMA AG Address before: British Ahmed Sykes Patentee before: Glaxo Group Ltd. Effective date of registration: 20151119 Address after: British Ahmed Sykes Patentee after: GLAXO Group Ltd. Address before: Delaware Patentee before: GLAXOSMITHKLINE LLC |